Global Market Size, Forecast, and Trend Highlights Over 2025-2037
Overactive Bladder Treatment Market size is anticipated to grow from USD 5.17 billion in 2024 to USD 12.31 billion by 2037, reflecting a CAGR of around 6.9% during the forecast period, from 2025 to 2037. Currently in 2025, the industry revenue of overactive bladder treatment is estimated at USD 5.42 billion.
The reason behind the growth is impelled by the growing number of pregnancies. Women go through hormonal changes during pregnancy, which may compromise bladder control and cause symptoms of overactive bladder. The hormone progesterone in particular may encourage bladder muscle relaxation, resulting in increased frequency and urgency of urinating.
The growing inclination toward minimally invasive procedures is believed to fuel the market growth. The need for a shorter hospital stay, less discomfort, and fewer complications has increased the preference for minimally invasive surgery among the general public worldwide. Nonpharmacological treatments such as oral medications have been found to lessen the signs and improve bladder function by strengthening the pelvic floor and altering behavior.
In addition, techniques including neuromodulation, sacral nerve stimulation, and percutaneous tibial nerve stimulation are among the minimally invasive procedures which have gained popularity since they can manage overactive bladder symptoms in patients without the requirement of any surgery. According to research, over 12 million laparoscopic procedures are performed across the globe every year.
Overactive Bladder Treatment Sector: Growth Drivers and Challenges
Growth Drivers
- Growing Geriatric Population– The elderly population is more prone to age-related changes to the urinary system and bladder which might lead to a rise in the incidence of overactive bladder. Reduced urethral sphincter tone, reduced bladder capacity, and diminished bladder muscular strength are some of the age-related changes observed in older people.
According to estimates, the number of individuals in the world who are 60 or older will increase to over 2 billion by 2050. - Rise in Adoption of Sedentary Lifestyles – The pelvic floor muscles, which are crucial for bladder control, might lose strength and tone as a result of a sedentary lifestyle. Overactive bladder (OAB) symptoms may result from weak pelvic floor muscles.
Besides this, a sedentary lifestyle may also raise the risk of getting urinary tract infections (UTIs), which could cause or aggravate overactive bladder symptoms in persons of all ages, including young adults.
Challenges
- High Cost of Treatment– For some people seeking therapy for an overactive bladder, the high expense of care might be a substantial deterrent. OAB treatment may involve a variety of alternatives, each with a different price tag, including dietary changes, prescription drugs, and medical procedures.
Some therapies used to treat OAB including antimuscarinic pharmaceuticals, may be pricey and need to be used for a long time, which might result in substantial out-of-pocket expenses for patients. In addition, some medical procedures, such as injections of botulinum toxin or sacral nerve stimulation could be expensive and may not be covered by insurance. - Limited Patient Awareness
- Side Effects of Medication
Overactive Bladder Treatment Market: Key Insights
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
6.9% |
|
Base Year Market Size (2024) |
USD 5.17 billion |
|
Forecast Year Market Size (2037) |
USD 12.31 billion |
|
Regional Scope |
|
Overactive Bladder Treatment Segmentation
Therapy (Anticholinergics, Mirabegron, Neurostimulation, Intravesical Instillation)
The neurostimulation segment is estimated to hold around 40% share of the overactive bladder treatment market in the coming years owing to the benefits offered by neurostimulation therapy. Overactive bladder (OAB) may be treated with neurostimulation, which uses a neurostimulator device to stimulate the sacral nerves. This has the potential to control bladder function and lessen the symptoms of OAB including frequent and urgent urination.
Moreover, neurostimulation is typically performed as an outpatient procedure and is comparatively non-invasive to other procedures. Additionally, compared to medicines, which could result in constipation, dry mouth, and other side effects neurostimulation has fewer systemic side effects.
Disease Type (Idiopathic Overactive Bladder, Neurogenic Overactive Bladder)
The idiopathic overactive bladder segment in the overactive bladder treatment market is set to garner a notable share of over 50% in the near future. Overactive bladder caused by idiopathic causes is more common than overactive bladder caused by neurogenic causes and the majority of OAB and detrusor overactivity instances are "idiopathic”. The symptoms describe OAB symptoms for which there is no underlying cause such as found in obesity. Since OAB symptoms including urge incontinence, and urine urgency could be effectively decreased or eliminated with overactive bladder treatment, it is often used to treat idiopathic OAB.
Our in-depth analysis of the global market includes the following segments:
|
Therapy |
|
|
Disease Type |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportOveractive Bladder Treatment Industry- Regional Synopsis
North American Market Forecast
Overactive bladder treatment market in North America is predicted to account for the largest share of over 40% by the end of 2037 impelled by the growing investment in healthcare. As a result, there is a growing awareness among people in the region about overactive bladder as a medical condition which makes it simpler for people with overactive bladder to get the care they need and the tools they require to manage their illness. According to estimates, health spending in the US increased by over 9% in 2020.
APAC Market Statistics
The Asia Pacific overactive bladder treatment market is estimated to be the second largest, during the forecast timeframe led by the growing prevalence of chronic conditions such as diabetes. For instance, diabetes is linked to nerve degeneration, which may hinder bladder function and induce overactive bladder symptoms. As a result, the need for overactive bladder treatment may increase in the area. According to estimates, India has the highest prevalence of diabetes in the world as more than 70 million people currently living with the disease and the figure is projected to rise to over 130 million by 2045.
Companies Dominating the Overactive Bladder Treatment Landscape
- Astellas Pharma, Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Pfizer, Inc.
- AbbVie Inc.
- Teva Pharmaceutical Industries Ltd.
- Mylan N.V.
- Endo International Plc.
- Johnson & Johnson Private Limited
- India Medtronic Private Limited
- Boston Scientific Corporation
- Cognetix Medical, Inc.
In the News
- Astellas Pharma, Inc. reported that the U.S Food and Drug Administration (FDA) had approved a supplemental New Drug Application (sNDA) for the use of mirabegron in combination with the muscarinic antagonist solifenacin succinate for the treatment of overactive bladder with symptoms of urge incontinence, urgency, and frequency.
- AbbVie Inc. announced that it has received approval from the U.S. Food and Drug Administration (FDA) for BOTOX the only exclusive neurotoxic, which provides a novel therapeutic alternative for the treatment of neurogenic detrusor overactivity in pediatric patients who are not well controlled by anticholinergic drugs. Further, BOTOX is one of the most extensively researched drugs in the world which is injected into muscles and also used to treat overactive bladder symptoms such as a strong need to urinate with urge urinary incontinence, urgency, and urinating frequently.
Author Credits: Radhika Pawar
- Report ID: 4868
- Published Date: Mar 20, 2025
- Report Format: PDF, PPT
